CV Sciences, Inc. (CVSI: OTCQB) | CV Sciences, Inc. Provides Details for Webcast Discussing Its CBD-Based Drug Development Program on November 10, 2016

OTC

CV Sciences, Inc. Provides Details for Webcast Discussing Its CBD-Based Drug Development Program on November 10, 2016

Nov 03, 2016

OTC Disclosure News Service

– CV Sciences, Inc. Provides Details for Webcast Discussing Its CBD-Based Drug Development Program on November 10, 2016

Company to Discuss Development Efforts and Market Potential of its Proprietary Lead Drug Candidate, CVSI-007

LAS VEGAS, NV–(Marketwired – November 03, 2016) – CV Sciences, Inc. (OTCBB: CVSI) (the “Company”, “CV Sciences”, “our” or “we”) will hold a webcast on Thursday, November 10, 2016 at 5:00PM Eastern Standard Time to discuss its drug development program and specifically its drug candidate utilizing synthetically-formulated CBD for use in treatment of smokeless tobacco addiction. Smokeless tobacco addiction is a huge unmet medical need, as there are currently no FDA-approved drugs to treat this widespread and deadly addiction. The current treatment market in the U.S. alone is estimated at greater than $2 billion.

The webcast can be accessed through the Investors section of the Company’s website, cvsciences.com, or, attendees may register at https://attendee.gotowebinar.com/register/7551888241656804868.

About CV Sciences, Inc.
CV Sciences, Inc. (OTCBB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Contact:
Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

Copyright © 2016 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply